Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Rabah Redjoul; Christine Robin; Laurent Softic; Clément Ourghanlian; Ludovic Cabanne; Florence Beckerich; Amandine Caillault; Alexandre Soulier; Pauline Daumerie; Slim Fourati; Sébastien Maury

doi:10.1001/jamanetworkopen.2025.33828

September 26, 2025JAMA Network OpenOpen Access

Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study finds that immune responses to RSV vaccination in patients may be compromised.
Evidence shows that allogeneic hematopoietic stem cell transplant recipients may not respond adequately to vaccination.
Cohort study analyzes the immune response to vaccination among allogeneic transplant recipients within this specific group.
Highlights the importance of tailored vaccination approaches for this vulnerable population.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Cohort study assesses immune response to RSV vaccination in allogeneic stem cell transplant patients, indicating potential immune challenges.

Abstract

This cohort study evaluates immune response to respiratory syncytial virus (RSV) vaccination in allogeneic hematopoietic stem cell transplant recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Redjoul et al. (2025) studied this question.

synapsesocial.com/papers/68d9051441e1c178a14f49ce https://doi.org/10.1001/jamanetworkopen.2025.33828

View Full Paper

Ask AI

Bookmark

Share

Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading